Ellagic acid (Gallogen), a thickened tetracyclic natural product, is a potent CK2 inhibitor (IC50=40 nM; Ki=20 nM) with ATP-competitive properties. Ellagic acid is an antioxidant and also possesses antiproliferative activity.

ATP competitive CK2:40 nM

METHODS: Human pancreatic cancer cell lines PANC-1, AsPC-1 and MIA PaCA-2 were treated with Ellagic acid (10-1000 µM) for 24-72 h. Cell viability was measured by MTT assay.
RESULTS: The proliferation of PANC-1 was inhibited by the addition of 10 µM Ellagic acid in a dose-dependent manner. The proliferation of AsPC-1 was inhibited by the addition of 100 µM Ellagic acid, while the proliferation of MIA PaCA-2 was inhibited only by the addition of 1000 µM Ellagic acid. [1]
METHODS: Human lung cancer cells A549 were treated with Ellagic acid (5-20 µM) for 48 h, and the expression levels of target proteins were detected by Western Blot.
RESULTS: Ellagic acid treatment significantly down-regulated the phosphorylation of PI3K and Akt in a dose-dependent manner. [2]

METHODS: To investigate the hepatoprotective effects on alcohol-induced liver disease (ALD), Ellagic acid (50-100 mg/kg suspended in 0.5% CMC-Na) was administered by gavage once daily for four weeks to ICR mice receiving 50% (v/v) alcohol orally daily.
RESULTS: Ellagic acid attenuated oxidative stress, inflammatory response, steatosis and gut microbiota dysbiosis in ALD mice. [3]